An interventional study of My MS Toolkit in Multiple Sclerosis and Multiple Sclerosis (MS), sponsored by University of Washington. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-09.
Sponsored by University of Washington · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Multiple Sclerosis by University of Washington — 7 open to participants now, 7 under way, none of them phase 3. Multiple Sclerosis · University of Washington.
Among the 28 studies in Multiple Sclerosis by University of Washington, this one is the 14th largest by planned enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2026, is one of 23 with no phase, and was the 26th registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →7 of the 28 studies in Multiple Sclerosis by University of Washington are open now, in 1 country. Recruiting first, the newest first:
University of Washington · Sites in United States
Ages 18+
University of Washington · Sites in United States
Ages 18+
University of Washington · Sites in United States
Ages 21–70
University of Washington · Sites in United States
Ages 18+ · Healthy volunteers
University of Washington · Sites in United States
Ages 18–70
By country, each count listing its studies:
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1
First in 2008; this study’s year is marked. 4 started in 2026.
This study's planned enrollment of 110 is above the median of 50 across 2,208 interventional studies indexed under Multiple Sclerosis.
Median enrollment 112 across the 25 interventional studies, 120 across the 3 observational. Of the 18 that completed or were terminated, 4 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Washington is the lead sponsor of 1,435 studies on the registry; 225 are open to participants now.
Of its 158 completed or terminated interventional studies of FDA-regulated products, 137 (87%) have results posted.
4 of the studies in Multiple Sclerosis by University of Washington that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06809192University of WashingtonFactorial Optimization Trial to Test Cognitive Behavioral Therapy Components for Multiple Sclerosis Fatigue | 2026-12-31 |
| NCT07673354University of WashingtonHome-based Spinal Cord Stimulation for Hand & Arm Function in MS | 2027-03-01 |
| NCT07723599University of WashingtonCombating Age-related Failure of Myelination in Multiple Sclerosis: An Exploratory Study | 2027-06 |
| NCT07636434University of WashingtonMy MS Toolkit: An Internet-Based Depression Self-Management Program for Adults Living With Multiple Sclerosis | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 28 studies in Multiple Sclerosis by University of Washington, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
We are conducting this study to test if the new Toolkit depression module is accessible and helpful for people with multiple sclerosis (MS) in decreasing depression severity.
First, we will modify My MS Toolkit to make it more helpful and relevant to adults with MS and depressive symptoms. We plan to add:
Second, we will evaluate the ease, convenience, and effectiveness of the improved My MS Toolkit. We will compare how well the Toolkit reduces people's feelings of depression compared to those who don't have access to the Toolkit. We will use website data to assess participant engagement and treatment ease, and explore factors like age, initial feelings of depression, and other symptoms that may impact outcomes. Understanding these factors will help determine who benefits most from My MS Toolkit and who might need different depression treatments.
Participants will either have access or no access to the Toolkit for 4 months and complete 3 online surveys over that time period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will be given access to the My MS Toolkit and encouraged to start their participation via a "Getting Started" page that provides guidance on how best to use the program's modules. This is accessed online via the Internet.
Device: My MS Toolkit
Participants will be notified of their assignment to the waitlist and told that they can continue to receive or seek care as they normally would, including care from their MS health care provider. After completion of the final 4-month assessment, usual care participants will obtain access to My MS Toolkit and will be encouraged to use it.
The My MS Toolkit is an online self-management intervention created for and in partner with people living with multiple sclerosis. With an approach based in cognitive behavioral therapy, this program guides users in building skills to help manage common symptoms of MS, such as fatigue, pain, and depression.
Depressive Symptom Severity
This will be measured using the Patient Reported Outcomes Measurement Information System (PROMIS) Short Form v1.0 Depression 8a. Change from pre- to post-treatment will be measured and compared between My MS Toolkit and usual care participants. Responses from each item will be summed to form a total raw score ranging from 4-20. Higher scores indicate higher self-reported levels of depressive symptoms.
Time frame: Baseline (prior to treatment), 12-week and 4-month
Sleep Disturbance
Change in sleep quality will be measured with the Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance Short Form 4a, version 1.0. Responses from each item will be summed to form a total raw score ranging from 4-20. Higher scores indicate higher self-reported levels of sleep disturbance.
Time frame: Baseline (prior to treatment), 12-week, and 4-month
Fatigue Severity
Change in fatigue severity will be measured with the Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue-MS Short Form 8a, version 1.0. Responses from each item will be summed to form a total raw score ranging from 8-40. Higher scores indicate higher self-reported levels of fatigue.
Time frame: Baseline (prior to treatment), 12-week, and 4-month
Fatigue Impact
Change in fatigue impact will be measured using the Modified Fatigue Impact Scale (MFIS). In the 21-item MFIS, participants rate their agreement with each statement on a 5-point Likert scale, from 0 = 'Never' to 4 = 'Almost always'.. Responses can add up to a total score (0-84) and subscales for physical (0-36), cognitive (0-40) and psychosocial functioning (0-8). Higher numbers indicate greater impact of fatigue on a person's activities.
Time frame: Baseline (prior to treatment), 12-week, and 4-month
Pain Intensity
Participant-rated pain intensity assessed via the 3-item Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Intensity scale. Raw scores range from 3-15. Higher scores indicate higher self-reported levels of pain intensity.
Time frame: Baseline (prior to treatment), 12-week, and 4-month
Anxiety
Change in symptoms of anxiety will be measured with the Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety Short Form 7a, version 1.0. Responses from each item will be summed to form a total raw score ranging from 7-35. Higher scores indicate higher self-reported levels of anxiety symptoms.
Time frame: Baseline (prior to treatment), 12-week, and 4-month
Pain Interference
Change in pain interference will be measured with the Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference Short Form 6a, version 1.1. Responses from each item will be summed to form a total raw score ranging from 6-30. Higher scores indicate higher self-reported levels of pain interference.
Time frame: Baseline (prior to treatment), 12-week, and 4-month
Social Participation
Change in pain interference will be measured with the Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference Short Form 6a, version 1.1. Responses from each item will be summed to form a total raw score ranging from 8-40. Higher scores indicate greater self-reported satisfaction and a higher quality of life regarding ability to engage with family, friends, and daily responsibilities.
Time frame: Baseline (prior to treatment), 12-week, and 4-month
Treatment Engagement
Treatment engagement will be assessed through examination of website analytic data such as number and duration of page visits.
Time frame: 12-week and 4-month
Treatment Satisfaction
Global assessment of treatment satisfaction will be measured by participant self-report on a scale of 0 (very dissatisfied) - 4 (very satisfied).
Time frame: 12-week and 4-month
Treatment Recommendation
Treatment recommendation will be measured using an adapted version of the NET Promoter Score. Participations will be asked how likely they are to recommend the treatment to a friend or colleague with MS and depression on a scale of 0 (Not at all likely) to 10 (Extremely likely).
Time frame: 12-week and 4-month
Perception of Change
Global impression of change will be measured by participant self-report. Participants will report, since the start of the study, how much they think their overall depression or depressive symptom severity has changed on a scale of 1 (no change) - 7 (A great deal better and a considerable improvement that has made all the difference).
Time frame: 12-week and 4-month
Self-Efficacy
Self-efficacy will be measured using the University of Washington Self-Efficacy Scale(UW-SES) 6a Short Form v1.0. Raw scores range from 6-30. Higher scores indicate greater belief in ability to manage challenges and achieve desired outcomes.
Time frame: Baseline (prior to treatment),12-week, and 4-month
Plan to share: Yes — Study data may be shared in de-identified form with outside researchers and collaborators as requested and deemed acceptable by study investigators.
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.
Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 12 months is below that.
Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.